SpeeDx Symposium

Friday 16th July 2021, 14.20-15.20 CET

Join us for our virtual symposium at the STI HIV 2021 World Congress. Register your interest below and enter the draw to win a ‘Giant Microbe.’


Gonorrhoea & Resistance Guided Therapy (RGT) – What is it? Why is it needed? & How can it be implemented?



As gonorrhoea AMR rates rise there is increasing value in utilising alternative treatment options as a strategy to preserve last line antibiotics. Helen Fifer, Public Health England, outlines the rationale of BASHH’s recommendation of RGT to facilitate use of alternate treatments for gonorrhoea. Dr. Andrew Winter, Consultant in Sexual Health and HIV, discusses the steps required and challenges overcome to effectively implement RGT into both a laboratory and clinical setting.


Dr Andrew Winter

PhD FRCP (Glasg) FRCP(Edin), FFCI

Dr Winter was appointed Consultant in Sexual Health and HIV in Glasgow,UK in 1999 after completing a PhD in Infection at Birmingham University. Dr Winter’s main interest is in digital health leadership: he led adoption of the national sexual health system in Scotland, was appointed as clinical e-Health lead in NHS Greater Glasgow and Clyde in 2015, and in 2020 became Vice-Chair of the Scottish Health and Care Digital Network. He was in the first cohort of the UK’s NHS Digital Academy and is a Fellow of the Faculty of Clinical Informatics. His clinical interests are in HIV care and STI diagnostic testing. He is a member of the European IUSTI Guidelines Group and UK Country Representative for IUSTI Europe.



Title: From lab to the clinic: finding your feet with molecular resistance testing

In this session we will share practical learning from our experience introducing molecular resistance testing for gonorrhoea in a large urban population in the UK. We will look at some of the implementation considerations such as laboratory test nomenclature, human factors issues in clinical electronic systems, and changes to service flow. We will describe some of the health technology systems that have helped, and emphasise the importance of close working between laboratory and clinical colleagues.

Supporting Speaker

Dr Elizabeth Moss

Clinical Fellow in Emergency Medicine, NHS Greater Glasgow and Clyde, UK

Dr Helen Fifer

Consultant Microbiologist, Public Health England

Dr Fifer is a Consultant Microbiologist at the National Infection Service, Public Health England, Colindale, where she is the lead microbiologist for bacterial STIs. She is a member of the BASHH Clinical Effectiveness Group and Bacterial Special Interest Group, and is the lead author of the BASHH Gonorrhoea treatment guidelines as well as the editor for the BASHH Mycoplasma genitalium guideline.



Title: Failure of empiric therapy for gonorrhoea

This talk will provide an overview of the emergence of resistance in Neisseria gonorrhoeae, illustrated by some cases of ceftriaxone-resistant gonorrhoea. The new UK guidelines and resistance-guided therapy will also be discussed.


Dr Charles Cartwright

Senior Vice President of Clinical Affairs, SpeeDx

Since 2019, Dr. Cartwright has served as Senior Vice President of Clinical Affairs for SpeeDx. Prior to that he was a Vice President and Discipline Director at the Laboratory Corporation of America (LabCorp), responsible for laboratory operations and research and development in molecular infectious diseases. Prior to joining LabCorp, he was the medical director of microbiology and molecular diagnostics at Hennepin County Medical Center in Minneapolis, MN.

Want to win a Giant Microbe?

Register your interest now to go into the draw to win a Giant Microbe

  • (Select from drop-down menu)
  • General Data Protection Regulation

  • Subscribe to SpeeDx electronic communications. Please check 'yes' to opt in. By clicking YES you are agreeing to the General Data Protection Regulation 2016/679
  • This field is for validation purposes and should be left unchanged.
Want more information?